From Tysabri to bapi and back to the drawing board: Dale Schenk speaks
This article was originally published in Scrip
Executive Summary
Dale Schenk is the scientist behind both the hugely successful multiple sclerosis treatment Tysabri (natalizumab) and the much-hyped investigational Alzheimer's disease vaccination bapineuzumab, which crashed spectacularly in Phase III trials last year. Now heading up the newly independent Prothena, which was demerged from Elan late last year, he speaks to Scrip's Eleanor Malone as he embarks on his third adventure as a biotech entrepreneur.
You may also be interested in...
Prothena Sees Potential In Targeting Amyloid, Validated By Biogen
Prothena views potential approval of Biogen’s aducanumab as a flag in the sand for next-generation amyloid-targeting therapies to race past, including the firm’s own antibody and vaccine programs.
Prothena CEO Dale Schenck Dies From Pancreatic Cancer
Prothena CEO Dale Schenk, the scientist behind innovative medicines that included bapineuzumab and Tysabri, died from pancreatic cancer on Sept. 30 – less than two years after he revealed his diagnosis.
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.